This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-27 and is reviewed periodically as new material appears.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Some supplements may help prevent migraine frequency or severity, including riboflavin (vitamin B2), vitamin D, magnesium, alpha-lipoic acid, and coenzyme Q10. Omega-3 fatty acids do not seem to help.
The δ13C of the emu's diet is reflected in the δ13C of the calcite of its egg shell. Small stones are swallowed to assist in the grinding up and digestion of the plant material. Individual stones may weigh 45 g (1.6 oz) and the birds may have as much as 745 g (1.642 lb) in their gizzards at one time. They also eat charcoal, although the reason for this is unclear. Captive emus have been known to eat shards of glass, marbles, car keys, jewellery and nuts and bolts. Emus drink infrequently but ingest large amounts when the opportunity arises. They typically drink once a day, first inspecting the water body and surrounding area in groups before kneeling down at the edge to drink. They prefer being on firm ground while drinking, rather than on rocks or mud, but if they sense danger, they often stand rather than kneel. If not disturbed, they may drink continuously for ten minutes. Due to the scarcity of water sources, emus are sometimes forced to go without water for several days. In the wild, they often share water holes with other animals such as kangaroos; they are wary and tend to wait for the other animals to leave before drinking.
Bursty: Data transfer is abrupt and does not include content such as video, audio, or other isochronous forms of data. Light: For most applications, packet sizes are limited to 256 bytes. Transmission of multiple consecutive packets may occur, but is generally avoided, if possible. Asynchronous: DASH7's main method of communication is by command–response, which by design requires no periodic network "hand-shaking" or synchronization between devices. Stealth: DASH7 devices do not need periodic beaconing to be able to respond in communication. Transitive: A DASH7 system of devices is inherently mobile or transitional. Unlike other wireless technologies, DASH7 is upload-centric, not download-centric, thus devices do not need to be managed extensively by fixed infrastructure, i.e., base stations.
=== Use of social media networks === Almost all Americans who were in their teens and 20s during the late 2010s and early 2020s are on at least one social-media platform. YouTube was the most popular in 2024, followed by TikTok, Instagram, and Snapchat. Meanwhile, Facebook and Twitter have lost grounds among teenagers compared to the 2010s. About three quarters checked their accounts multiple times a day. Members of Generation Z are more likely to "follow" others on social media than "share" and use different types of social media for different purposes. Very few expressed concern about third parties being able to access their data as they share more personal information more often compared to previous generations. Most have uploaded photographs of themselves, stated their interests, given their school names, posted their locations, and revealed their relationship statuses. As a cohort, Generation Z finds validation and social support on social media, where they develop their own individual identities. On the other hand, only a minority engaged in political conversations on social media networks. Despite their heavy usage of social media, a majority believe that life was better before the emergence of these platforms.
== Professional organizations for clinical data management == International Network of Clinical Data Management Associations (INCDMA) aims at the promotion of collaboration among clinical data management groups around the world. It is an international forum for discussion of and feedback on current topics of relevance to the discipline of CDM. It is composed of members the boards of the SCDM, ACDM, DMB (France), PSDM (The Netherlands) who participate in the INCDMA proceedings and funding. It also regroups DM leaders and subject matter experts from Europe, North America, Israel, Japan, China and Australia. The Association for Clinical Data Management (ACDM) is a global organization founded in 1987 and is Empowering Excellence in Clinical Data Management. The ACDM represents a vibrant community of dedicated clinical research professionals who are passionate about enhancing the drug development process through fostering an environment that encourages continuous learning and the practical application of modern Clinical Data Management practices. With over 35 years of service to the data management community, the ACDM's unwavering commitment is to provide clear and effective platforms for its members to network, share experiences, and stay abreast of the latest regulations and standards in Clinical Data Management. Along with supporting members on their professional development journeys, offering opportunities to gain the skills and insights needed to excel in their careers and shape the future of data management.
Sources: en.wikipedia.org
Protein design is the rational design of new protein molecules to design novel activity, behavior, or purpose, and to advance basic understanding of protein function. Proteins can be designed from scratch (de novo design) or by making calculated variants of a known protein structure and its sequence (termed protein redesign). Rational protein design approaches make protein-sequence predictions that will fold to specific structures. These predicted sequences can then be validated experimentally through methods such as peptide synthesis, site-directed mutagenesis, or artificial gene synthesis. Rational protein design dates back to the mid-1970s. Recently, however, there were numerous examples of successful rational design of water-soluble and even transmembrane peptides and proteins, in part due to a better understanding of different factors contributing to protein structure stability and development of better computational methods.
== Structure == Leprecan, also known as P3H1, forms a tight complex with CRTAP and cyclophilin B (PPIB), a collagen processing enzyme complex named PCP complex (P3H1-CRTAP-PPIB). Cryo-electron microscopy (cryo-EM) studies have revealed that the PCP complex consists of P3H1, CRTAP, and PPIB in a 1:1:1 stoichiometry. The complex features a "face-to-face" spatial arrangement, with the prolyl hydroxylation site of the C-terminal domain of P3H1 and the prolyl isomerization site of PPIB positioned at the "top" of the complex. Below these dual-catalytic sites lies an X-shaped base formed by CRTAP and the N-terminal domain of P3H1, which exhibit similar 3D foldings. The surface of the PCP complex also harbors several potential collagen-binding sites, as indicated by EM density corresponding to a synthetic peptide with the COL1A1 sequence. Furthermore, the PCP complex has the ability to dimerize, forming a hexameric structure.
==== Acquired ==== Acquired Von Willebrand syndrome can occur due to autoantibodies, either interfering with platelet or collagen binding; increasing VWF clearance from the plasma; adsorption to myeloma cells or platelets; or proteolytic cleavage of VWF after shear stress-induced unfolding. A form of acquired VWD occurs in patients with aortic valve stenosis, leading to gastrointestinal bleeding (Heyde's syndrome). This form of acquired VWD may be more prevalent than is presently thought. In 2003, Vincentelli et al. noted that patients with acquired VWD and aortic stenosis who underwent valve replacement experienced a correction of their hemostatic abnormalities, but that the hemostatic abnormalities can recur after 6 months when the prosthetic valve is a poor match with the patient. Similarly, acquired VWD contributes to the bleeding tendency in people with an implant of a left ventricular assist device (a pump that pumps blood from the left ventricle of the heart into the aorta).
== History == Van Gieson’s stain was first described by Ira T. Van Gieson in 1889 as a method for examining nervous system tissue. Van Gieson was a pathologist who published The Laboratory notes of technical methods for the nervous system in 1889, introducing the picric–fuchsin method at that time. In early 20th century the stain was combined with other techniques. In 1908, Friedrich hermann verhoeff introduced an iron–hematoxylin stain for elastic fibers, which used with Van Gieson’s counterstain to form the Verhoeff–Van Gieson (VVG) stain. In VVG staining, elastic fibers are stained black (by Verhoeff’s hematoxylin), collagen appears red (by Van Gieson), and cytoplasm elements are yellow.
Sources: en.wikipedia.org
=== Negative health effects === Felony drug convictions often lead to circumstances that carry negative health-related consequences. Employment opportunities (and associated healthcare benefits), access to public housing and food stamps, and financial support for higher education are all jeopardized, if not eliminated, as a result of such a conviction. In addition, a felony distribution charge often precludes a convict from benefiting from most healthcare programs that receive federal funding.
In April 2025, Santiago Peña received Yu-Lin Huang, secretary-general of Taiwan's International Cooperation and Development Fund (ICDF), to strengthen bilateral cooperation, especially in technological innovation. Initiatives for the development of artificial intelligence (AI) were discussed, including the creation of a data center and the training of human talent in this field. The installation of a regional AI center in Paraguay was proposed as part of a strategy to promote technological development in the country.
== Structure == Muscle cells are grouped into muscle fascicles by enveloping perimysium connective tissue. Fascicles are bundled together by epimysium connective tissue. Muscle fascicles typically only contain one type of muscle cell (either type I fibres or type II fibres), but can contain a mixture of both types.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.